Boston Scientific Reports Officer Changes and Financials
Ticker: BSX · Form: 8-K · Filed: Nov 19, 2025 · CIK: 885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2025 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, financial-reporting
Related Tickers: BSX
TL;DR
BSX filed an 8-K detailing leadership changes and financial updates as of Nov 18, 2025.
AI Summary
Boston Scientific Corporation (BSX) filed an 8-K on November 19, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the earliest event reported as November 18, 2025.
Why It Matters
This filing indicates potential shifts in the company's leadership and provides updated financial information, which could influence investor decisions.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance and financial updates, not indicating any immediate significant risks.
Key Players & Entities
- BOSTON SCIENTIFIC CORP (company) — Registrant
- BSX (company) — Ticker Symbol
- November 18, 2025 (date) — Earliest event reported
- November 19, 2025 (date) — Filing date
FAQ
What specific officer positions were affected by the changes reported in the 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers', but does not specify the exact positions in the provided text.
Are there any details about new directors elected to the board?
The filing mentions the 'Election of Directors' as an item of information, but specific names or details of newly elected directors are not present in this excerpt.
What types of compensatory arrangements are being disclosed?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not provided in this section.
What financial statements are included with this 8-K filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific content or nature of these statements is not detailed in the provided text.
What is the primary business of Boston Scientific Corporation?
Boston Scientific Corporation is in the 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS' industry, with SIC code 3841.
Filing Stats: 1,772 words · 7 min read · ~6 pages · Grade level 18 · Accepted 2025-11-19 16:20:18
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share BSX New York Stock
Filing Documents
- bsx-20251118.htm (8-K) — 40KB
- ex101-2026annualbonusplan.htm (EX-10.1) — 84KB
- ex102-2026tsroverview.htm (EX-10.2) — 72KB
- ex103-2026organicnetsaleso.htm (EX-10.3) — 32KB
- image_0.jpg (GRAPHIC) — 43KB
- image_0a.jpg (GRAPHIC) — 1KB
- 0000885725-25-000052.txt ( ) — 444KB
- bsx-20251118.xsd (EX-101.SCH) — 3KB
- bsx-20251118_def.xml (EX-101.DEF) — 15KB
- bsx-20251118_lab.xml (EX-101.LAB) — 27KB
- bsx-20251118_pre.xml (EX-101.PRE) — 16KB
- bsx-20251118_htm.xml (XML) — 4KB
01 FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit No. Description 10.1* Boston Scientific Corporation 2026 Annual Bonus Plan, effective as of January 1, 2026 10.2* Boston Scientific Corporation 2026 Relative Total Shareholder Return Performance Share Program 10.3* Boston Scientific Corporation 2026 Organic Net Sales Growth Performance Share Program 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Documents filed or furnished with this report. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 19, 2025 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary